Search

everythinglearnresearchcommunity

for

Search:↓

A specific genetic trait in tumor cells is linked to longer survival without disease in certain lymphoma patients.

The article's correction clarifies scientific and methodological concerns about miR-200c-3p's role in alopecia areata.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.

Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.

A young woman had a rare skin reaction to a medication for her joint disease, and a combination therapy improved her condition.

Baricitinib effectively treats both rheumatoid arthritis and alopecia areata.

BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.

A patient with Crohn's disease grew back their hair after stopping Adalimumab, which had caused hair loss.

New vitamin D3 forms need the vitamin D receptor to reduce fibrosis in human cells.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Doxil is an effective, modified chemotherapy drug with a unique toxicity profile and shows promise in treating certain cancers.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.

Cedrol may help reduce liver fat and fat cell growth caused by corticosteroids.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

The method effectively delivers vaccines through the skin without needles.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

DOPE:DOPC liposomes can improve targeted cancer drug delivery, reducing side effects and increasing effectiveness.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

A woman's hair loss during Hepatitis C treatment with PEG-INF-a-2a and Ribavirin was reversible after stopping the medication.

UDCA reduces inflammation and joint damage in rheumatoid arthritis.

CB-03-04 shows promise as a treatment for prostate issues due to its strong anti-androgen effects.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Combining DEB-BACE with chemotherapy is more effective and has fewer side effects than chemotherapy alone for treating unresectable lung squamous cell carcinoma.

The compound 4c showed strong potential as an anticancer agent.

Baricitinib significantly improves hair regrowth in severe alopecia areata.

Social media can help compare the effectiveness and safety of new arthritis medications.

LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.

Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.